Phase 1 Study of AMX-818 Monotherapy and Combination with Pembrolizumab in Advanced or Metastatic HER2-Expressing Cancers

The primary objective of this study is to evaluate the **safety** and effects of AMX-818, both as a monotherapy and in combination with **pembrolizumab**, in participants with locally advanced or metastatic **HER2-expressing cancers**. This is a Phase 1, first-in-human trial, which is crucial for determining the initial safety profile and potential therapeutic effects of AMX-818 in this patient population. Understanding the safety and effects of this treatment is clinically relevant as it may offer new therapeutic options for patients with HER2-expressing cancers, which are often aggressive and have limited treatment options.

The clinical trial involves a total of **405 participants** diagnosed with **locally advanced or metastatic HER2-expressing cancers**. The study population includes both male and female subjects, encompassing an age range that corresponds to categories 3 and 4, which typically include adults and older adults. Participants were selected based on specific criteria, although detailed inclusion or exclusion criteria are not provided. The trial population includes individuals from a vulnerable population, indicating a need for careful ethical considerations. Lifestyle factors such as diet, physical activity, or habits are not specified in the available data. The sponsor has not provided additional information regarding the general health status or specific lifestyle considerations of the participants.

The clinical trial is a **Phase 1** study designed to evaluate the safety and effects of AMX-818, administered alone or in combination with pembrolizumab, in participants with locally advanced or metastatic **HER2-expressing cancers**. The trial employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from the recruitment start date on April 30, 2022, to the anticipated end date on August 31, 2027.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve comprehensive evaluations to confirm the presence of HER2-expressing cancers and other inclusion parameters. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are scheduled to monitor safety, assess treatment effects, and collect necessary data for the study's endpoints. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to evaluate the overall impact of the treatment.

The expected length of participant involvement in the trial is contingent upon the individual's response to the treatment and the overall study timeline. Participants may be subject to early termination from the study if they experience adverse effects, fail to comply with study protocols, or if the study is discontinued for any reason. The trial is conducted in accordance with ethical standards and regulatory requirements to ensure participant safety and data integrity throughout the study period.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on April 30, 2022, with an estimated completion date of August 31, 2027. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize a combination of clinical observations and laboratory tests to gather initial efficacy data. The methods for measuring and analyzing efficacy parameters are not specified, but such trials generally employ validated scales and laboratory tests to ensure accurate and reliable data collection. The trial's design and execution will adhere to rigorous scientific standards to evaluate the investigational product's potential benefits.